Skip to Content

Notice

Withdrawal of 53 Guidances on Individual Product Labeling

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice; withdrawal.

SUMMARY:

The Food and Drug Administration (FDA) is announcing the withdrawal of 53 individual product labeling guidances. The guidances are being withdrawn because they are outdated and of little use to the generic drug industry. The agency has developed other guidance and resources to assist industry in obtaining up-to-date labeling for reference listed drugs.

DATES:

General comments on agency guidance documents are welcome at any time.

ADDRESSES:

Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.fda.gov/​dockets/​ecomments. Submit written requests for the guidance for industry entitled “Revising ANDA Labeling Following Revision of the RLD Labeling” to the Division of Drug Information (HFD-240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. See the SUPPLEMENTARY INFORMATION section for electronic access to agency guidance documents.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Rita Hassall, Center for Drug Evaluation and Research (HFD-600), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5845.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA is announcing the withdrawal of 53 individual product labeling guidances. These labeling guidances, currently available on the Center for Drug Evaluation and Research (CDER) guidance list, were intended to provide sponsors of abbreviated new drug applications (ANDAs) with product specific templates for package insert labeling that would be accepted by the Office of Generic Drugs (OGD). Package insert labeling for innovator products changes frequently, and it is difficult to keep the guidances updated. The guidances are being withdrawn because they are outdated and of limited use to the generic drug industry.

The withdrawal of these 53 product specific labeling guidances is part of a long-term effort in OGD to review guidance documents on the development of generic drug products with the goal of identifying documents that need to be revised, reformatted, or withdrawn because they are no longer current (64 FR 36886, July 8, 1999).

The following guidances are withdrawn:

GuidanceDate of Issuance
Acetaminophen, Aspirin and Codeine Phosphate Tablets and Acetaminophen, Aspirin and Codeine Phosphate CapsulesRevised December 1993
Acetaminophen and Codeine Phosphate Oral Solution and Oral SuspensionRevised December 1993
Alprazolam TabletsRevised August 1996
Amiloride Hydrochloride and Hydrochlorothiazide Tablets USPSeptember 1997
Amlodipine Besylate TabletsSeptember 1997
Astemizole TabletsSeptember 1997
Atenolol TabletsAugust 1997
Butalbital, Acetaminophen and Caffeine Tablets USP or Butalbital, Acetaminophen and Caffeine Capsules USPSeptember 1997
Butalbital, Acetaminophen, Caffeine and Hydrocodone Bitartrate TabletsSeptember 1997
Butorphanol Tartrate Injection USPRevised October 1992
Captopril and Hydrochlorothiazide Tablets USPApril 1995
Captopril TabletsFebruary 1995
Carbidopa and Levodopa Tablets USPRevised February 1992
Cimetidine Hydrochloride InjectionSeptember 1995
Cimetidine Tablets USPRevised September 1995
Cisapride Oral SuspensionSeptember 1997
Cisapride TabletsSeptember 1997
Clindamycin Phosphate Injection, USPRevised September 1998
Diclofenac Sodium Delayed-Release TabletsRevised February 1995
Diltiazem Hydrochloride Extended-Release CapsulesRevised September 1995
Start Printed Page 44858
Diphenoxylate Hydrochloride and Atropine Sulfate Oral Solution USPApril 1995
Diphenoxylate Hydrochloride and Atropine Sulfate Tablets USPApril 1995
Fludeoxyglucose F18 InjectionJanuary 1997
Flurbiprofen Tablets USPRevised January 1994
Fluvoxamine Maleate TabletsSeptember 1997
Gentamicin Sulfate Ophthalmic Solution USP and Gentamicin Sulfate Ophthalmic Ointment USPRevised April 1992
Heparin Sodium Injection USPRevised March 1991
Hydrocodone Bitartrate and Acetaminophen Tablets USPRevised April 1994
Indomethacin Capsules USPRevised September 1995
Itraconazole CapsulesSeptember 1998
Leucovorin Calcium for InjectionJuly 1996
Leucovorin Calcium Tablets USPJuly 1996
Medroxyprogesterone Acetate Tablets USPRevised September 1998
Metaproternol Sulfate Inhalation Solution USPRevised May 1992
Metaproterenol Sulfate Syrup USPRevised May 1992
Metaproterenol Sulfate Tablets USPRevised May 1992
Metoclopramide Tablets USP and Metoclopramide Oral Solution USPRevised February 1995
Naproxen Sodium Tablets USPSeptember 1997
Naproxen Tablets USPSeptember 1997
Paclitaxel InjectionSeptember 1997
Quinidine Sulfate Tablets, USPOctober 1995
Ranitidine Tablets USPRevised November 1993
Risperidone Oral SolutionSeptember 1997
Risperidone TabletsSeptember 1997
Sulfacetamide Sodium Ophthalmic Solution USP and Sulfacetamide Sodium Ophthalmic Ointment USPRevised August 1993
Sulfacetamide Sodium and Prednisolone AcetateRevised January 1995
Sulfamethoxazole and Trimethoprim Tablets USP and Sulfamethoxazole and Trimethoprim Oral Suspension USPRevised August 1993
TheophyllineRevised February 1995
Theophylline Intravenous Dosage FormsSeptember 1995
Tobramycin Sulfate Injection USPRevised May 1993
Venlafaxine Hydrochloride TabletsOctober 1997
Verapamil Hydrochloride TabletsOctober 1991
Zolpidem Tartrate TabletsSeptember 1997

In May 2000, the agency issued the guidance for industry entitled “Revising ANDA Labeling Following Revision of the RLD Labeling.” This guidance provides information on how to access current package insert labeling on OGD's Labeling Review Branch Web site at http://www.fda.gov/​cder/​ogd/​rld/​labeling_​review_​branch.htm.

Interested persons may submit written or electronic comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Persons with access to the Internet may obtain CDER guidance documents at http://www.fda.gov/​cder/​guidance/​index.htm.

Start Signature

Dated: June 24, 2002.

Margaret M. Dotzel,

Associate Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 02-16796 Filed 7-3-02; 8:45 am]

BILLING CODE 4160-01-S